STRS Ohio’s Lipocine LPCN Stock Holding History

STRS Ohio’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-324	Closed	-$20.1K	–	1932
2016 Q2	$16K	Buy	+324	New	+$50.2K	﹤0.01%	1871

Other funds holding LPCN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

STRS Ohio's LPCN Position: Q3 2016 in Review

STRS Ohio sold out of Lipocine (LPCN) in Q3 2016, closing a stake of 324 shares — an estimated $20.1K sold.

STRS Ohio first reported a position in LPCN in Q2 2016 and held it in 1 quarter. The position peaked at $16K in Q2 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q3 2016.

STRS Ohio reported no remaining Lipocine position as of Q3 2016 after selling out during the quarter.
STRS Ohio sold 324 Lipocine shares in Q3 2016, an estimated $20.1K.
STRS Ohio first reported a position in Lipocine in Q2 2016 and held it in 1 quarter.
STRS Ohio's Lipocine position peaked at $16K in Q2 2016.
47 funds tracked by Wall St. Rank held Lipocine as of Q3 2016.

Based on STRS Ohio's 13F filing for Q3 2016, filed 27 Oct 2016.